These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 36264573)
1. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans. Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573 [TBL] [Abstract][Full Text] [Related]
2. Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Sama S; Kerrigan K; Sinnott JA; Puri S; Akerley W; Haaland B; Patel S Cancer Treat Res Commun; 2023; 35():100686. PubMed ID: 36736060 [TBL] [Abstract][Full Text] [Related]
3. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. Kim E; Biswas T; Bakaki P; Dowlati A; Sharma N; Machtay M Pract Radiat Oncol; 2016; 6(5):e163-e169. PubMed ID: 27142494 [TBL] [Abstract][Full Text] [Related]
4. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients. Hatfield LA; Huskamp HA; Lamont EB J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949 [TBL] [Abstract][Full Text] [Related]
5. Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. Jiang S; Huang L; Zhen H; Jin P; Wang J; Hu Z BMC Cancer; 2021 Dec; 21(1):1308. PubMed ID: 34876060 [TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer. Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506 [TBL] [Abstract][Full Text] [Related]
7. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937 [TBL] [Abstract][Full Text] [Related]
8. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L; Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097 [TBL] [Abstract][Full Text] [Related]
9. Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial. Yu TT; Hu X; Liufu WJ; Niu SQ; Lian HM; Ma HL; Wang J; Bao Y; Chen M; Peng F Cancer Med; 2024 Apr; 13(8):e7215. PubMed ID: 38659392 [TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy. Valette CA; Filleron T; Debieuvre D; Lena H; Pérol M; Chouaid C; Simon G; Quantin X; Girard N Respir Med Res; 2023 Nov; 84():101012. PubMed ID: 37307617 [TBL] [Abstract][Full Text] [Related]
11. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241 [TBL] [Abstract][Full Text] [Related]
12. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients]. Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206 [No Abstract] [Full Text] [Related]
13. Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review. Sun A; Durocher-Allen LD; Ellis PM; Ung YC; Goffin JR; Ramchandar K; Darling G Curr Oncol; 2019 Jun; 26(3):e372-e384. PubMed ID: 31285682 [TBL] [Abstract][Full Text] [Related]
14. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study. Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N; Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. Shimokawa T; Okamoto H; Machida R; Misumi Y; Hosomi Y; Yoneshima Y; Tanaka H; Okishio K; Simizu J; Goto K; Akamatsu H; Kubota K; Nakagawa K; Horinouchi H; Ando M; Kataoka T; Ohe Y Lung Cancer; 2023 Jul; 181():107195. PubMed ID: 37156212 [TBL] [Abstract][Full Text] [Related]
17. Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer. Kim H; Choi E; Heo MH; Kim JY; Park KU Oncology; 2022; 100(6):313-319. PubMed ID: 35390786 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005 [TBL] [Abstract][Full Text] [Related]
19. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW; Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988 [TBL] [Abstract][Full Text] [Related]
20. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Glisson B; Besse B; Dols MC; Dubey S; Schupp M; Jain R; Jiang Y; Menon H; Nackaerts K; Orlov S; Paz-Ares L; Ramlau R; Tang R; Zhang Y; Zhu M Clin Lung Cancer; 2017 Nov; 18(6):615-625.e8. PubMed ID: 28601388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]